»Mission
Topigen uses its expertise in respiratory disease research
and proprietary gene-based therapies to create novel, synergistic
and cost-effective topical products for asthma, COPD, allergic
rhinitis and associated conditions with unmet therapeutic needs
for the global marketplace.
About UsScienceInvestorsMedia CenterContact Us
Our Therapeutic Focus


Asthma
TPI ASM8 is a multitargeted compound which effectively blocks two major arms of the inflammatory response in asthma.

COPD
TPI 1020 and TPI 1100 are two compounds being developed for the treatment of COPD.

Allergic Rhinitis
TPI ARL8, a compound with the same mechanism of action as TPI ASM8, is being studied in allergic rhinitis.
News

2008-08-14

Topigen Pharmaceuticals appoints Mark Parry-Billings, Ph.D., as Chief Executive Officer

2008-07-23

Topigen Pharmaceuticals completes enrollment of Phase II clinical study of TPI ASM8 in asthma

2008-06-19

Topigen Pharmaceuticals presents at BIO 2008 in San Diego.

logo allergen

AllerGen-Topigen Industrial Research and Development Fellowship
AllerGen NCE Inc., the Allergy, Genes and Environment Network and Topigen offer a post-doctoral position in industrial research and development - an opportunity to work for two years at Topigen's facility in Montreal, Quebec.
Applications deadline September 1, 2008.

Click here for details on how to apply:
www.AllerGen-nce.ca.


footer_line
Copyright © 2005-2008, Topigen Pharmaceuticals Inc.
All rights reserved. Terms of Use.